A Randomized Study of the Efficacy of a New Intervention for Medication Adherence in Chronic Illness: Medications, Meaning and Me (The 3-M Study)

August 19, 2016 updated by: Duke University

Purpose of the study - The purpose of this study is to develop and evaluate the efficacy of a new, theoretically based intervention to improve medication adherence in persons with HF. The hypotheses include:

Hypothesis I. Poorly adherent patients with symptomatic HF who receive the intervention (n=40) will be more adherent to medicines during the12-month intervention than a control group (n=40) of poorly adherent patients with symptomatic HF.

Hypothesis II. Poorly adherent patients with symptomatic HF who receive the intervention (n=40) will have fewer hospital readmissions (HR) and emergency department (ED) visits during the 12-month intervention than a control group of poorly adherent patients with symptomatic HF.

Study Activities and population - A prospective, randomized controlled design will be used to pilot test the efficacy of a new intervention to promote adherence to the medication regimen in chronic heart failure in the clinical setting. The initial development and feasibility testing of the intervention is complete (Preliminary Work, Section 4.5).

Patients with HF symptom exacerbation (n = 80) who exhibit high likelihood of poor adherence, as determined by a validated screening measure, the Medication Adherence Scale (MAS)89 at baseline assessment, will be recruited and randomized to receive the intervention or usual care with attention control. Medication adherence, symptom frequency and intensity, hospital readmissions (HR) and emergency department (ED) visits will be assessed in both groups at 3, 6 and 12-month clinic visits. The intervals between visits are considered sufficient to minimize sensitization bias to psychometric measures. Longitudinal measurement is required to evaluate the magnitude of change in adherence and symptom-related events occurring over time. Efficacy will be measured as improved adherence (primary outcome) and decreased HR and ED visits (secondary outcomes) in the intervention group as compared to the attention control group at 12 months. The study will close when all patients have had a 12-month post-enrollment clinic visit.

Data Analysis & Safety/Risk Considerations - The investigators will use generalized linear models to test the primary and secondary hypotheses (McCullagh and Nelder, 1989). Logistic generalizations of the traditional, multivariate GLM are appropriate when the dependent variable is binary and the probability of an event is modeled, as is the case with adherence in this study. When the dependent variable is a count, a commonly used generalized model uses the natural logarithm of the count, as with re-hospitalizations and ED visits in this study. In compliance with NIH guidelines for data safety and monitoring activities, a number of quality control steps will be used to ensure the on-going safety of participants and the scientific integrity of this feasibility intervention study. The proposed study poses only very minimal risks to participants. All participants will receive usual care. Participation in the study will not replace patients' regular health care attention. Data safety will be monitored by the PI, the Data Safety Officer (Dr. Karl Swedberg), and the study co-investigators. Any adverse events will be reported immediately to the Duke IRB and the NIH.

Data Safety. First, a project database will be constructed, using participant ID numbers and including all demographic, pre- and post-intervention history and all assessment materials. A separate file, cross-referencing participant identification with project ID numbers, will be maintained with access limited to the PI or a designated member of the investigative team.

Study Overview

Study Type

Interventional

Enrollment (Actual)

87

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • > 18 years old
  • symptomatic heart failure
  • telephone required

Exclusion Criteria:

  • heart failure due to congenital etiology
  • patients who cannot provide self-care

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: behavioral intervention
Patient education for self-management called "CHIME 3-M" will be delivered
behavioral intervention for self-management in heart failure
Active Comparator: control
attention control arm received phone calls to discuss non-heart failure related health topics
patients will receive phone calls regarding health-related topics not associated with heart failure

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change in medication adherence
Time Frame: baseline (0), 3, 6, and 12 months
Nurse-observed pill count, the primary measure of adherence, was collected at baseline (0), 3, 6, and 12 months.
baseline (0), 3, 6, and 12 months
change in medication adherence based on the MAS
Time Frame: baseline (0), 3, 6, and 12 months
The study team also collected the Morisky Medication Adherence Scale (MAS) at baseline (0), 3, 6, and 12 months.
baseline (0), 3, 6, and 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change in belief in medications
Time Frame: baseline (0), 3, 6, and 12 months
Horne "Belief in Medications Questionnaire" (BMQ) was collected at baseline (0), 3,6, and 12 months
baseline (0), 3, 6, and 12 months
change in symptom frequency
Time Frame: baseline (0), 3,6, and 12 months
count of patient-reported symptom onset was collected at baseline (0), 3,6, and 12 months
baseline (0), 3,6, and 12 months
change in hospital readmissions
Time Frame: baseline (0), 3, 6, and 12 months
Readmissions were reviewed with patients at baseline (0), 3, 6, and 12 months.
baseline (0), 3, 6, and 12 months
change in Emergency Department visits
Time Frame: baseline (0), 3, 6 and 12 months
Emergency department visits were reviewed with patients at baseline (0), 3, 6 and 12 months.
baseline (0), 3, 6 and 12 months
change in satisfaction with Information about Medicines (SIMS)
Time Frame: baseline (0), 3, 6, and 12 months
The questionnaire "satisfaction with information about medicines" was collected at baseline (0), 3, 6, and 12 months
baseline (0), 3, 6, and 12 months
change in Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time Frame: baseline (0), 3, 6, and 12 months
The questionnaire "KCCQ" was collected at baseline (0), 3, 6, and 12 months
baseline (0), 3, 6, and 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: bradi b granger, PhD, Duke University School of Nursing

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2009

Primary Completion (Actual)

September 1, 2013

Study Completion (Actual)

September 1, 2013

Study Registration Dates

First Submitted

October 3, 2014

First Submitted That Met QC Criteria

October 6, 2014

First Posted (Estimate)

October 7, 2014

Study Record Updates

Last Update Posted (Estimate)

August 22, 2016

Last Update Submitted That Met QC Criteria

August 19, 2016

Last Verified

October 1, 2014

More Information

Terms related to this study

Other Study ID Numbers

  • Pro00019792
  • 1R03NR011500-01 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Self-management in Heart Failure

Clinical Trials on CHIME 3-M

Subscribe